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Overexpression of Neu (ErbB-2/HER2) is found in
;20% of breast tumors. Activation of Neu by a point
mutation (NeuT) causes constitutive tyrosine kinase ac-
tivity of this transmembrane receptor and transforming
activity in fibroblasts. To identify downstream targets
of Neu, we have analyzed the ability of Neu to activate
gene expression. Expression of NeuT, but not normal
Neu, caused transcriptional activation of Ets, AP-1, or
NF-kB-dependent reporter genes. Dominant inhibitory
Ras or Raf mutants blocked the Neu-mediated transcrip-
tional activation, confirming that Ras signaling path-
ways were required for this activation. Analysis with
Ets2 mutants indicated that activation of Ets2 transcrip-
tional activity mediated by NeuT or oncogenic Ras re-
quired phosphorylation of the same Ets2 residue, thre-
onine 72. Cotransfection of dominant inhibitory Ets2
mutants specifically blocked NeuT-mediated activation
of Ets-dependent reporter genes. Furthermore, in focus
formation assays using NIH 3T3 cells, the transforming
activity of NeuT was inhibited 5-fold when NeuT was
cotransfected with a dominant negative Ets2 mutant.
However, parallel colony formation assays showed that
the Ets2 dominant negative mutant did not inhibit the
growth of normal cells. Together, these data show that
NeuT activates a variety of transcription factor families
via the Ras signaling pathway and that Ets activation is
required for NeuT-mediated cellular transformation.
Thus, downstream targets of Neu, including Ets tran-
scription factors, may be useful points for therapeutic
intervention in Neu/ErbB-2-associated cancers.
The c-neu oncogene product (also called ErbB-2 or HER2) is
a 185-kDa transmembrane receptor tyrosine kinase that be-
longs to the epidermal growth factor family (1–3). Overexpres-
sion of Neu/ErbB-2 is found in 20–30% of human breast
cancers and is also seen in ovarian, lung, and gastric adeno-
carcinomas (4–8). A number of potential activating ligands for
Neu/c-ErbB-2 have been studied (8), and this receptor can be
constitutively activated by a point mutation in the transmem-
brane domain (9) or by deletions in the extracellular domain
(10, 11). Constitutive activation by mutation causes Neu to
exhibit strong transforming activity, both in cultured cells and
in transgenic mice (9, 12). Expression of very high levels of
normal Neu can transform fibroblasts in vitro (13). Overexpres-
sion of normal Neu in transgenic mice also leads to tumor
formation, but because these tumors are infrequent and focal,
it appears that a second event is required for tumor formation
(14, 15). Cellular transformation is associated with alter-
ations in the expression of multiple genes, many of which are
likely regulated by the abundance or activity of specific tran-
scription factors. Although downstream targets of Neu have
been identified, like other receptor tyrosine kinases, the
details of the pathways for cellular transformation remain
unclear (16, 17).
Neu that has been activated by a point mutation in the
transmembrane domain (called NeuT) has enhanced tyrosine
kinase activity (9) and has been found to activate a variety of
signaling pathway components (18). NeuT-activated signaling
components include phospholipase Cg and phosphatidylinosi-
tol 39-kinase (19, 20), Src (21, 22), Shc, and Grb2/SOS (23–25).
More downstream signaling components activated by NeuT
also include Ras, mitogen-activated protein kinases, and AP-1
activity (24, 26, 27). Therefore, although mutations in ras are
rarely found in breast cancer, the Neu-mediated activation of
Ras signaling pathway components suggests that this pathway
may nonetheless play an important role in breast cancers (28).
We have focused on transcription factor activation by onco-
genes (29, 30), because there is a close correlation between the
ability of non-nuclear oncogenes to activate gene expression
and to transform cells (31, 32). We previously examined the
requirements for promoter DNA binding sites that could func-
tion as Ras responsive elements, and found that at the right
spacing and orientation, two or more binding sites for members
of either the Ets, AP-1 or NF-kB transcription factor families
are sufficient to confer Ras responsiveness (29). The impor-
tance of oncogene-mediated transcription factor activation is
revealed by the findings that inhibition of either AP-1 or Ets
activation blocks Ras-mediated cellular transformation (33–
36). In the present study, we have determined that NeuT in-
creases the activities of several different families of transcrip-
tion factors, including Ets, AP-1, and NF-kB, and that
activation of these downstream targets is mediated by the Ras
signaling pathway. We further show evidence that NeuT and
oncogenic Ras share a common molecular target for activating
transcription, by mediating the phosphorylation of Ets2 thre-
onine 72, leading to increased Ets2 transactivation activity.
Finally, to examine the biological significance of Ets activa-
tion, we have used dominant negative Ets mutants to show
that Ets activation is required for NeuT-mediated cellular
transformation.
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EXPERIMENTAL PROCEDURES
Plasmid Construction—The minimal promoter reporter plasmid
D56FosdE-CAT,1 and its derivatives containing the E.18 (two overlap-
ping head-to head Ets2 binding sites), Py (overlapping Ets and AP-1
binding sites), 6AP-1 (six adjacent AP-1 binding sites), or HIV NF-kB
(two adjacent NF-kB binding sites) oncogene response elements have
been described previously (29). The 2CRE reporter gene was con-
structed by inserting two tandem copies of a double-stranded oligonu-
cleotide containing the somatostatin CRE (tcgaTACGGTGACGTCA-
GAGAG) into D56FosdE-CAT. The expression vector for normal Neu
(pSV2neuN) and for oncogenic Neu (pSV2neuT) have been described
previously (9), as has the expression constructs for oncogenic Ras,
pZIPrasH(61L) (37), and dominant inhibitory Ras, pZIPrasH(17N) (38),
and dominant inhibitory Raf, Raf-N3 (39).
The FNpcDNA3 expression vector was constructed using the cyto-
megalovirus promoter-driven expression vector pcDNA3 (Invitrogen,
San Diego, CA), and inserting between the HindIII and BamHI sites a
peptide leader sequence encoding MDYKDDDDKPKKKRKVGS, pre-
ceded by a consensus translational start site (GCCACC). This leader
sequence contains the FLAG epitope tag and the SV40 nuclear local-
ization signal. The Ets2 coding sequence was modified to insert into this
vector by standard polymerase chain reaction mutagenesis, by addition
of an in-frame BamHI site (GGA TCC) at the 59 end and a SmaI site just
39 of the termination codon. The BamHI-SmaI cut Ets2 coding sequence
was inserted into the BamHI-EcoRV cut FNpcDNA3 vector, to create
FN-Ets2. The Ets2 coding sequence inserted directly into pcDNA3 gave
the same results as the epitope tagged FN-Ets2 construct.2 Mutant
FN-Ets2 constructs with altered residue 72 were constructed using the
Chameleon site-directed mutagenesis kit (Stratagene, La Jolla, CA) as
recommended by the manufacturer. The Ets dominant negative mu-
tants were constructed using the FNpcDNA vector in the same manner
as full-length Ets2. E2TAD contains Ets2 residues 1–331, and E2DBD
contains Ets2 residues 332–468. Similarly, E1TAD contains Ets1 resi-
dues 1–305, and E1DBD contains residues Ets1 residues 306–466.
DNA Transfections and CAT Assay—The growth of NIH 3T3 cells
and their transfection by the calcium phosphate method, as well as
assays for reporter gene expression and normalization, have been de-
scribed previously (29, 30). Cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% calf serum, and for transient
transfections, were split to 1 3 106 cells/60-mm dish the day prior to
transfection. This cell density gave a maximal transactivation response
with NeuT. The day after transfection, the cells were refed with Dul-
becco’s modified Eagle’s medium containing 0.5% calf serum and incu-
bated for an additional 48 h prior to harvest for the TLC-based CAT
assay. For cAMP induction, 0.5 mM isobutylmethylxanthine and 10 mM
forskolin (final concentrations) were added to the media the final 16 h
prior to harvest. All of the CAT assay results are the average of at least
three separate experiments quantitated using a phosphorimager (Bio-
Rad), and the standard deviations for each experiment are shown. For
analysis of Ets2 protein levels, the transfected cells were treated the
same as for the CAT assay, except that for the 4 h prior to harvest, the
cells were metabolically labeled with [35S]methionine. The cell labeling
and subsequent quantitation of the amount of epitope-tagged Ets2
protein following immunoprecipitation using the anti-FLAG M2 mono-
clonal antibody (Eastman Kodak Co.) and SDS-polyacrylamide gel elec-
trophoresis, was performed as described previously (40).
Focus Formation Assay—Focus formation assays following calcium
phosphate transfection of NIH 3T3 cells were performed as described
previously (41), with 250 ng of pSV2neuN or pSV2neuT plasmid DNA.
The focus formation results for each cotransfection are the average
number of foci from two separate experiments on a total of six dishes.
For the G418-resistant colony formation assay, 3 days after transfec-
tion, the cells were placed in media containing 400 mg/ml G418,
and G418-resistant colonies were allowed to grow out as described
previously (41).
RESULTS
Transforming Neu Activates Transcription of Ets, AP-1, and
NF-kB-dependent Reporter Genes—To test the effects of normal
and activated Neu/ErbB-2 on transcription factor activation,
transient cotransfection experiments were performed in NIH
3T3 cells. Oncogene expression constructs or empty expression
vectors were cotransfected with reporter plasmids containing
oncogene response elements. We have previously characterized
the requirements for several kinds of promoter elements that
can confer Ras responsiveness, by placing synthetic transcrip-
tion factor binding sites just upstream of a minimal promoter
fused to the CAT gene. While the minimal promoter-CAT re-
porter gene (D56FosdE) is not transcriptionally activated by
cotransfection with oncogenic Ras, expression of reporter plas-
mids containing multiple Ets, AP-1, or NF-kB binding sites is
strongly activated by oncogenic Ras (29). We have now used
these reporter plasmids to determine what families of tran-
scription factors are activated by normal c-Neu (NeuN) or
transforming Neu (NeuT), which contains an activating point
mutation (Val664 to Glu) in the transmembrane domain (9).
The results of cotransfection experiments (Fig. 1) showed
that expression of NeuT activated the transcription of the re-
porter genes containing synthetic binding sites for Ets (E.18),
AP-1 (6AP-1), or NF-kB (NF-kB), and a reporter gene contain-
ing single overlapping Ets and AP-1 binding sites (Py). Expres-
sion of NeuN did not significantly activate reporter gene ex-
pression (data not shown). The transcriptional activation for
each reporter gene was measured by determining the ratio of
the CAT activity from cells transiently cotransfected with Neu
expression construct relative to cells cotransfected with empty
pSV2 expression plasmid. The transcription of the minimal
promoter-containing CAT reporter construct, D56FosdE, was
not significantly activated by NeuT (Fig. 1). However, the tran-
scriptional activation by NeuT of reporter genes containing Ets,
AP-1, or NF-kB binding sites ranged from 8.6-fold for the E.18
reporter to 20.6-fold for the NF-kB reporter (Fig. 1). The dif-
ference in transactivation activity between the expression plas-
mids for NeuN and NeuT, which differ by only a single nucleo-
1 The abbreviations used are: CAT, chloramphenicol acetyltrans-
ferase; DBD, DNA binding domain; TAD, transactivation domain.
2 C. K. Galang, J. J. Garcı́a-Ramı́rez, and C. A. Hauser, unpublished
data.
FIG. 1.NeuT-induced transcription activation of Ets, AP-1, and
NF-kB-dependent reporter genes. Reporter plasmid DNA (3 mg of
D56FosdE or 1 mg or the other reporters) and either pSV2neuT or pSV2
(4 mg) were cotransfected in to NIH 3T3 cells, and the resulting CAT
activity was determined. The fold activation is the ratio of the CAT
activity from each reporter gene in the presence of pSV2neuT, relative
to the CAT activity from the same reporter gene with empty pSV2
expression vector. The bar graph results display the average of at least
three separate experiments, and the standard deviation is shown by
error bars.
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tide, parallels the difference in their transformation activity,
because pSV2neuT, but not pSV2neuN, can transform NIH 3T3
cells (9). Under the conditions of this assay, oncogenic Ras
activated the transcription of these reporter genes to an even
higher level than NeuT (data not shown). To demonstrate the
specificity of NeuT-mediated activation, we tested whether the
expression of a reporter gene containing 2 copies of the soma-
tostatin CRE was activated by NeuT. This cAMP response
element has been previously shown to confer cAMP-responsive-
ness, but not Ras-responsiveness (42). The 2CRE reporter gene
was not transactivated by NeuT (Fig. 1) or by oncogenic Ras,
but was transactivated approximately 10-fold by treatment of
the cells with forskolin and isobutylmethylxanthine to induce
cAMP levels (data not shown). Similar to the results we previ-
ously found for oncogenic Ras (29), reporter genes containing
the minimal fos promoter with only a single added binding site
for Ets, AP-1, or NF-kB family members were not significantly
transactivated by expression of NeuT (data not shown), indi-
cating that the presence of a single binding site for any of these
transcription factors was not sufficient to create an Neu re-
sponsive promoter element.
Transcription Activation by NeuT Uses the Ras Signaling
Pathway—A variety of components of the Ras signaling path-
way have been found to be activated by NeuT. Therefore, to
determine whether activation of Ras and Raf are involved in
the observed transcription factor activation by NeuT, expres-
sion constructs for dominant inhibitory mutants of Ras or Raf
were cotransfected along with NeuT and the reporter plasmids.
Expression of the RasH(Asn17) mutant and the truncated
Raf-N3 mutant proteins interfere with the activation of endog-
enous Ras and Raf, respectively (39, 43). The data in Fig. 2
show that the NeuT-mediated activation of Ets, AP-1, or NF-kB
transcription factor activity was strongly inhibited by either
dominant negative Ras or Raf. These data suggest that activa-
tion of Ras and Raf are essential components of the signaling
pathway for activation of these three families of transcription
factors by NeuT.
Ets2 Is a Downstream Target of NeuT—We have previously
found that Ets-2 is a target for oncogenic Ras signaling and
that cotransfection of expression constructs for oncogenic Ras
and Ets2 results in very high levels of the Ets-dependent E.18
reporter gene expression (29, 40). To determine whether Ets2 is
a target of NeuT signaling, we first tested whether NeuT could
synergize with Ets2 to superactivate the E.18 reporter gene.
Transfection of 100 ng of the FN-Ets2 expression construct
alone activated the E.18 reporter gene expression 4-fold, and
NeuT activated E.18 expression 6-fold (Fig. 3A). However,
when the same amount of Ets2 expression construct was co-
transfected with NeuT, E.18 expression was activated by 33
fold (Fig. 3A). Thus, NeuT can synergistically activate tran-
scription of the E.18 reporter when coexpressed with Ets2,
suggesting Ets2 is indeed a target of NeuT signaling. This
Ras/Ets2 synergy, was termed “superactivation,” and we have
shown previously, using a combination of biochemical and ge-
netic approaches, that Ras-dependent phosphorylation of Ets2
Thr72 is essential for superactivation by oncogenic Ras. Substi-
tution of Ets2 Thr72 with Ala or Glu abolishes Ras superacti-
vation of Ets2 activity, whereas substitution of Thr72 with Ser
(which preserves the putative mitogen-activated protein kinase
recognition site) has little effect (40). To determine if NeuT
activation of Ets2 activity has similar requirements to activa-
tion by oncogenic Ras, we tested the ability of NeuT to super-
activate E.18 expression in combination with Ets2 residue 72
mutants. Like Ras, NeuT did not superactivate E.18 expression
when cotransfected with Ets2 Ala72 or Glu72 mutants, but did
superactivate expression when cotransfected with Ets2 Ser72
(Fig. 3A). To determine whether NeuT alters the amount or the
transcriptional activity of Ets2 and whether the mutant Ets2
proteins are expressed equivalently to the wild type, we meas-
ured the Ets2 protein levels in the cotransfected cells. Quanti-
tation by phosphorimager of the immunoprecipitated labeled
Ets2 signals shown in Fig. 3B, revealed that there was not a
significant increase in Ets2 levels caused by coexpression of
NeuT and that there was only a 10% difference in the amounts
of Ets2(Ala72) and wild type Ets2(Thr72) proteins present in
the transfected cells. Furthermore, in this experiment, there
was actually almost 2-fold more of the nonactivable Ets2(E72)
mutant than the wild type. Therefore, the NeuT-mediated
superactivation of Ets2 activity resulted from altered trans-
activation activity and not increases in Ets2 protein levels.
Furthermore, because this pattern of NeuT-mediated transcrip-
tional activation in combination with Ets2 mutants was the
same as that we previously found mediated by oncogenic Ras
(40), these results strongly suggest that phosphorylation of
Ets2 Thr72 is a common molecular target of both NeuT and
oncogenic Ras signaling.
Two Types of Dominant Negative Ets2 Mutants Block Tran-
scriptional Activation by NeuT and Oncogenic Ras—The strong
transcriptional activation by NeuT of the E.18 reporter gene,
whose promoter consists of two synthetic Ets2 consensus DNA
binding sites inserted into a minimal promoter, suggested that
Ets proteins are downstream targets of NeuT signaling. We
then tested whether two different types of Ets2 dominant neg-
ative mutants could interfere with NeuT transactivation of
Ets-dependent reporter genes. One of these inhibitory mutants
contains the same portion of Ets2 as a previously described
construct which suppresses Ras-mediated transactivation (35).
This ETS domain-containing portion of Ets2 (see Fig. 4A) func-
tions as the DNA binding domain, and we called this construct
E2DBD. The corresponding Ets1 construct, E1DBD, was also
tested for its activity. The E2DBD and E1DBD proteins were
very potent inhibitors of Ets activity, as 50 ng of cotransfected
E2DBD plasmid was enough to nearly abolish either NeuT or
FIG. 2. NeuT-induced transcription activation is Ras- and Raf-
dependent. The CAT cotransfection assays and determination of fold
activation by NeuT were the same as for Fig. 1, except that 3 mg of an
additional expression plasmid was cotransfected with the reporter and
Neu expression plasmids. The added plasmids were either pZIP vector,
(solid bars), pZIPrasH(17N) (striped bars), or Raf-N3 (open bars).
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oncogenic Ras-mediated transactivation of the E.18 reporter
gene (Fig. 4, B and C), and of the Py reporter gene (data not
shown).
The other type of Ets2 inhibitory mutant we tested consisted
of the Ets2 sequences lacking the DNA binding domain (Fig. 4).
This portion of Ets2 contains the transactivation domains of
Ets2 (44, 45) including a predicted helix-loop-helix domain (46),
and we called this construct E2TAD. The only known ETS
family member to contain extensive identity to Ets2 in this
region is Ets1, making this putative dominant negative mutant
potentially more specific. We also tested the corresponding
Ets1 transactivation domains construct, E1TAD. High level
expression of either E2TAD or E1TAD (4 mg of cotransfected
plasmid) also strongly inhibited E.18 reporter gene activation
by either NeuT (Fig. 4B) or oncogenic Ras (Fig. 4C) and of the
Py reporter gene (data not shown). Plasmid titration studies
revealed that inhibition of NeuT or Ras-mediated transactiva-
tion by the E2TAD expression construct required 30–100 fold
more expression plasmid DNA than was required with E2DBD,
and Western blot analysis revealed that this difference was
reflected in protein levels, as substantially more TAD protein
than DBD protein was required for dominant negative function
(data not shown). However, the observed inhibition of both
types of Ets dominant negative mutants was specific, and fur-
thermore, not due to inhibition of Neu expression, because
control experiments showed that Neu-mediated activation of
the AP-1 dependent reporter gene, 6AP-1, was not inhibited by
either of the Ets dominant negative constructs (Fig. 4B). Sim-
ilar specificity was seen with Ras-mediated activation, as Ets-
dependent, but not AP-1-dependent reporter gene activation
was strongly inhibited by Ets dominant negative mutants (data
not shown).
Dominant Negative Ets2 Suppresses Cellular Transforma-
tion by NeuT—When the neu coding sequence is placed in an
expression plasmid containing the SV40 promoter, activated
NeuT, but not normal NeuN, is highly transforming for NIH
3T3 cells (9). To determine whether the NeuT-mediated activa-
tion of Ets-dependent transcription described above is an im-
portant component of the cellular transformation pathway of
NeuT, we tested the effect of a strong dominant negative Ets2
mutant on cellular transformation. NIH 3T3 cell focus forma-
tion assays showed that transfection of 250 ng of pSV2neuT
DNA caused an average of 51 foci per dish, whereas the equiv-
alent amount of pSV2neuN DNA or an empty vector pZIP
caused no foci (Fig. 5). For the focus inhibition assay, 50 ng of
DNA of either empty expression vector (FNpcDNA3), or domi-
nant negative Ets1 (E1DBD), or dominant negative Ets2
(E2DBD) expression constructs were cotransfected along with
250 ng of pSV2neuT DNA. While cotransfection of the empty
expression vector did not significantly reduce focus formation,
dominant negative Ets1 and Ets2 reduced focus formation by
1.7- and 5.7-fold, respectively (Fig. 5). When 1 mg of dominant
negative expression plasmid was used, there was some nonspe-
cific inhibition of focus formation by FNpcDNA3 (2.1-fold) but
strong inhibition of focus formation by E1DBD (5.7-fold) or
E2DBD (8.8-fold). To determine whether the Ets dominant
negative mutants were blocking focus formation by toxicity or
growth inhibition, parallel colony formation experiments were
carried out in NIH 3T3 cells. The FNpcDNA3 vector, with
which the EtsDBD constructs were made, confers resistance to
G418. The average number of G418-resistant colonies obtained
with 50 ng of FNpcDNA3, Ets1DBD, or Ets2DBD was 12, 12,
FIG. 3. NeuT-mediated enhance-
ment of Ets2 activity targets Ets2 res-
idue 72. A, CAT cotransfection assays
were performed using the E.18 reporter
gene (1.5 mg) and 100 ng of the indicated
Ets2 expression plasmid, along with 4 mg
of empty expression vector (pSV2, open
bars) or NeuT expression vector (pSV2-
neuT, closed bars). The fold activation and
error bars were determined as described
in Fig. 1. B, immunoprecipitation analy-
sis of Ets2 protein levels. Cells were co-
transfected with the Ets2 expression con-
struct indicated beneath each lane or with
no expression vector denoted by “(2),” and
either pSV2 or pSV2neuT. The cells were
treated as in Fig. 3A, except that they
were metabolically labeled with [35S]me-
thionine for 4 h prior to harvest. Subse-
quently, the cells were lysed and the tran-
siently expressed epitope tagged Ets2
proteins were immunoprecipitated, sepa-
rated by SDS-polyacrylamide gel electro-
phoresis, and visualized by autoradiogra-
phy (see “Experimental Procedures”). The
specific Ets2 signal is indicated with an
arrow.
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and 9 colonies/ng of plasmid DNA, respectively, with no ob-
served difference in colony size. There was also not a significant
difference between the number or size of G418 resistant colo-
nies obtained using 1 mg of the empty vector compared with the
dominant negative Ets constructs (data not shown). Together,
the results of the focus inhibition and colony formation assays
indicated that the Ets1 and Ets2 dominant negative mutants
inhibited NeuT-mediated cellular transformation without
blocking normal cell growth.
DISCUSSION
The neu oncogene product has been reported to activate an
array of signaling molecules, the most downstream of which is
AP-1 transactivation activity, which results in increased AP-1-
dependent gene expression (27). The purpose of the current
study was to identify other downstream targets of NeuT by
determining whether NeuT mediates activation of other tran-
scription factor families, and to assess the biological signifi-
cance of NeuT-mediated transactivation. Therefore, we used
cotransfection analysis with NeuT expression plasmids and
reporter genes that we had shown previously to be activated by
oncogenic Ras (29). These reporter genes contained synthetic
transcription factor binding sites placed in front of a minimal
promoter-CAT reporter gene and allow analysis of the activa-
tion of specific transcription factor families by oncogenes (29).
This analysis showed that the transactivation activity of Ets
and NF-kB transcription factors, as well as AP-1, is activated
by NeuT, but not NeuN. These results form the basis for more
detailed future studies to determine which individual members
of these large transcription factor families are targets of NeuT.
As an example of such analysis, we have shown here, using
cotransfection studies with wild-type and mutant Ets2 pro-
teins, that Ets2 is a downstream target of NeuT. The observed
NeuT-mediated transcriptional activation was not simply a
consequence of NeuT increasing cell growth or generally stim-
ulating transcription, because the minimal promoter-CAT re-
porter gene alone (D56FosdE) or reporter plasmids containing
nonfunctional oncogene response elements had clearly meas-
urable basal levels of expression but were not transactivated by
NeuT. Furthermore, a reporter gene inducible by signals dis-
tinct from the Ras pathway, the cAMP-inducible reporter gene
2CRE, was also not transcriptionally activated by NeuT. The
finding that dominant negative Ras or Raf blocked transcrip-
tion factor activation indicated that an essential component of
NeuT signaling is the Ras signaling pathway. However, be-
cause transcriptional activation was measured after 2 days of
coexpression, this inhibition by dominant negative Ras and Raf
does not necessarily mean that there is a direct linear pathway
from Neu through Ras and Raf. For example, it is possible that
Neu behaves similar to Raf, which stimulates the production of
autocrine factors which in turn activate other components of
the Ras signaling pathway (47). The fact that Ets2 is a down-
stream target of Neu is intriguing, given the finding that there
is a binding site for an unidentified ETS protein in the pro-
moter of the HER/neu gene that influences its expression (48).
Although we found that the three families of transcription
factors examined were induced in parallel by NeuT and onco-
genic Ras in NIH 3T3 cells, the transcription signaling path-
ways of these oncogenes do not appear to be identical. Two
FIG. 4. Dominant negative Ets mutants block E.18 transactiva-
tion by Neu or Ras. A, schematic representation of the Ets2 protein,
with the potential helix-loop-helix region denoted by HLH. The regions
present in the truncated E2TAD and E2DBD mutants are indicated. B,
CAT cotransfection assays were performed with 1 mg of E.18 reporter
plasmid (solid bars) or of 6AP-1 reporter (striped bars) the indicated
amounts of Ets dominant negative construct and 4 mg of either pSV2 or
pSV2neuT expression construct. Fold activation was determined as in
Fig. 1. C, CAT cotransfection assays as described in B, except that the
E.18 reporter gene was cotransfected with the indicated amount of Ets2
dominant negative expression construct and either 2 mg of pZIP or
pZIPrasH(L61).
FIG. 5. Dominant negative Ets mutants inhibit NeuT-mediated
cellular transformation. Results of focus formation assay using 6-cm
dishes of NIH 3T3 cells transfected with 250 ng of the indicated onco-
gene expression construct. Where indicated below, 250 ng of pSV2neuT
was cotransfected with 50 ng of empty expression vector (FNpcDNA3)
or dominant inhibitory Ets plasmids (E1DBD or E2DBD). Each bar
graph shows the average of six plates from two separate experiments,
and the standard deviation is indicated by error bars.
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examples of differential gene regulation by Ras and Neu that
are found in Ras transformed cells, but not in the same cell
lines transformed with NeuT, are the elevation of the transcrip-
tion of the parathyroid hormone-related peptide gene (49) and
decreased expression of the NF-1/CTF gene (50).
A question that arises from our transactivation results, is
why overexpression of normal Neu, which is the defect in
Neu/ErbB-2 associated with human cancers, did not signifi-
cantly activate transcription factor activity in our assays. One
possible explanation is that normal Neu requires its ligand to
stimulate transcription, and this ligand is not present in the
mouse fibroblasts. In fact, studies where the normal Neu/
ErbB-2 receptor was stimulated with antibodies or by using a
hybrid epidermal growth factor-Neu receptor and epidermal
growth factor or with heregulin and cotransfected ErbB-3, the
same activation of signal transduction (including AP-1 activa-
tion), is seen as with NeuT (51–55). A second partial explana-
tion may be that while previous studies of human breast tu-
mors found no activating Neu/ErbB-2 mutations (56, 57), many
activated Neu mutants may not have been detected. Recent
work with transgenic mice overexpressing normal Neu has
revealed that in 65% of the tumors examined, the neu gene
contained an activating mutation, but outside of the previously
examined sequences encoding the transmembrane domain
(11). Another potential reason that NeuN was not active in the
transactivation assay is that the pSV2neuN expression con-
struct does not sufficiently overexpress Neu to achieve the
amplified levels of Neu/ErbB-2 found in human tumors. In
support of this idea is the finding that transfection of
pSV2neuN does not transform cells (Ref. 9 and see Fig. 5),
whereas transfection of an expression plasmid that causes
much higher levels of normal Neu expression can transform
NIH 3T3 cells (13).
Because oncogene expression can have widespread effects on
cells, it was important to establish whether NeuT-mediated
activation of Ets transcription factors is an necessary compo-
nent of NeuT-mediated cellular transformation. For this anal-
ysis, we made the dominant inhibitory Ets mutants. The trun-
cated Ets mutants that expressed only the Ets1 or Ets2 DNA
binding domains (DBD) were potent inhibitors of Ets-depend-
ent transcription activation by NeuT or Ras. Presumably these
mutant proteins act by binding to Ets binding sites, and block-
ing the function of endogenous Ets proteins. These mutant
proteins may effectively compete with the endogenous protein
due to the loss of the postulated intramolecular inhibition of
DNA binding present in full-length Ets1 and Ets2 (58, 59). It is
likely that E2DBD or E1DBD inhibit the activity of most ETS
family members, due to the similarity of ETS family DNA
binding sites (60). The potential for cross-inhibition of ETS
family members was illustrated by a recent study in which
overexpression of either of two of the most divergent ETS
domains, Ets1 or PU.1, has similar inhibitory effects on Ras-
mediated transactivation and transformation (36). We found
that overexpression of the transactivation domains (TAD) of
Ets1 or Ets2 also blocked NeuT-mediated activation of Ets-de-
pendent transcription, but much less efficiently than the DBD
mutants. We postulate that the TAD mutants act by titrating
out some limiting Ets interaction partner. However, the inhi-
bition of transactivation by TAD is not a generalized squelch-
ing of all transcription or by inhibiting NeuT expression, be-
cause neither the TAD nor the DBDmutants efficiently blocked
the NeuT or Ras-mediated activation of an AP-1-dependent
reporter gene.
The potential biological importance of the activation of Ets-
dependent transcription by NeuT was revealed by the observa-
tion that the Ets dominant negative mutant Ets2DBD specifi-
cally inhibited NeuT-mediated focus formation over 5-fold in an
NIH 3T3 cell cotransfection assay (Fig. 5). Thus, Ets mutants
that blocks NeuT-mediated transcriptional activation of an Ets-
dependent reporter gene also block cellular transformation. We
do not yet understand why the Ets1DBD mutant inhibited
NeuT-mediated focus formation less efficiently than Ets2DBD,
but this inhibition was still significant. We have further found
that both Ets1DBD and Ets2DBD inhibit focus formation by
oncogenic Ras and that the Ets2DBD mutant also inhibits this
focus formation more efficiently than Ets1DBD.3 The results of
the colony formation assay, in which equivalent numbers and
size of G418-resistant colonies were obtained with empty ex-
pression vector or EtsDBD mutants indicated that these dom-
inant negative mutants did not block focus formation by growth
inhibition or toxicity. Thus, with the appropriate expression of
an Ets dominant negative protein, it appears that NeuT-medi-
ated cellular transformation can be blocked without interfering
with normal cell growth. It has previously been found that Ras
transformed cells can actually be reverted to normal morphol-
ogy and growth characteristics upon expression of dominant
negative Ets (35, 36), and it will now be of great interest to
determine whether introduction of dominant negative Ets mu-
tants can revert NeuT transformed cell lines or human breast
cancer cell lines back to nontransformed cells. Previous exper-
imental approaches to inhibiting Neu/ErbB-2-mediated cellu-
lar transformation and tumor growth have largely been based
on directly interfering with Neu/ErbB-2 function, either with
dominant negative ErbB-2 mutants, antibodies against
ErbB-2, or ErbB-2 antisense oligonucleotides (61–65). The re-
sults described here suggest that inhibiting targets well down-
stream of Neu/ErbB-2, including activation of transcription
factors, may complement other approaches for therapy in tu-
mors associated with Neu/ErbB-2.
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